CMOs Focus on Technology Improvements

Over the past decade, planned average annual capacity growth in the biopharmaceutical contract manufacturing industry has slowed. This situation reflects both recent market conditions and a shift in investment priorities by biopharmaceutical contract manufacturing organizations.
CMOs have realigned their investment plans to focus on productivity improvements, lower costs, ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

User Input
Do not put any letters or characters here if you are not a spy program.